Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from CVRx ( (CVRX) ) is now available.
On August 4, 2025, CVRx announced the appointment of Brent Binkowski as Chief Operating Officer, effective August 11, 2025. Binkowski brings over 20 years of experience in medical devices, which is expected to enhance CVRx’s operations. The company reported a 15% increase in total revenue for the second quarter of 2025, reaching $13.6 million, driven by growth in the U.S. heart failure market. The number of active implanting centers in the U.S. grew by 27% since June 2024. CVRx is also benefiting from favorable CMS proposals for Barostim reimbursement, positioning the company for continued growth.
The most recent analyst rating on (CVRX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on CVRx stock, see the CVRX Stock Forecast page.
Spark’s Take on CVRX Stock
According to Spark, TipRanks’ AI Analyst, CVRX is a Neutral.
The overall score reflects strong revenue growth and positive market momentum, tempered by significant profitability and valuation challenges. The company’s strategic initiatives and long-term optimism are positive, but short-term disruptions and financial inefficiencies weigh on the score.
To see Spark’s full report on CVRX stock, click here.
More about CVRx
CVRx is a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases. Their flagship product, Barostim, is an FDA-approved implantable device that uses neuromodulation to alleviate heart failure symptoms.
Average Trading Volume: 331,958
Technical Sentiment Signal: Sell
Current Market Cap: $197.1M
See more data about CVRX stock on TipRanks’ Stock Analysis page.